文献速递中医内科中药与中成药合理使用针灸推拿

柴胡治疗急性无并发症呼吸道感染:随机对照试验系统评价

Bupleuri radix for Acute Uncomplicated Respiratory Tract Infection: A Systematic Review of Randomized Controlled Trials.
PubMed 文献 · Front Pharmacol · 2022-02-04

该系统评价纳入7项随机对照试验共910例急性上呼吸道感染患者,评估柴胡不同给药途径的疗效与安全性。低至极低确定性证据显示柴胡穴位注射可缩短退热时间并提高48小时内退热比例,柴胡丸剂解热效果与对乙酰氨基酚相似,但柴胡肌注联合维生素退热效果不及利巴韦林联合维生素。

要点

  • 柴胡穴位注射较安慰剂显著缩短退热时间(MD -33.32小时)并提高48小时退热比例(RR 14)。
  • 柴胡穴位注射联合常规治疗较单用常规治疗第1天降温更显著(MD -1.00°C)。
  • 仅2项试验报告不良事件,柴胡组未发生不良事件,证据确定性低至极低。

核心结论

  • 低或极低确定性证据表明柴胡(注射液和丸剂)对急性上呼吸道感染发热患者有解热作用,但对其他症状无效应。
  • 上述发现需设计良好、样本量充足的临床试验进一步证实。

研究设计与样本

  • 系统评价检索4个英文和4个中文数据库,截至2021年6月,纳入评估柴胡治疗急性无并发症呼吸道感染疗效的随机对照试验。
  • 共纳入7项随机对照试验,涉及910例急性上呼吸道感染患者,采用Cochrane RoB 2.0评估偏倚风险,RevMan 5.4进行数据分析,GRADEpro评估证据确定性。

主要发现

  • 柴胡穴位注射对比安慰剂:退热时间MD -33.32小时(95%CI -35.71, -30.93),48小时内退热比例RR 14(95%CI 1.96, 99.94)。
  • 柴胡穴位注射联合常规治疗对比单用常规治疗:治疗开始第1天体温MD -1.00°C(95%CI -1.19, -0.81)。
  • 柴胡丸剂解热效果与对乙酰氨基酚相似;柴胡肌注联合维生素对比利巴韦林联合维生素未显示退热效果。
  • 口服柴胡注射液溶液、丸剂和柴胡汤剂对比单用常规治疗,在改善急性上呼吸道感染整体症状(包括鼻分泌物和咳嗽两个关键症状)方面效果相似。

关键数值与推荐

  • 退热时间MD -33.32小时(95%CI -35.71, -30.93),对象为急性上呼吸道感染发热患者,干预为柴胡穴位注射对比安慰剂。
  • 48小时内退热比例RR 14(95%CI 1.96, 99.94),对象为急性上呼吸道感染发热患者,干预为柴胡穴位注射对比安慰剂。
  • 第1天体温MD -1.00°C(95%CI -1.19, -0.81),对象为急性上呼吸道感染患者,干预为柴胡穴位注射联合常规治疗对比单用常规治疗。

临床怎么用

  • 对于急性上呼吸道感染发热患者,可考虑柴胡穴位注射作为辅助退热手段,但需知晓证据确定性低至极低。
  • 柴胡丸剂可作为对乙酰氨基酚的替代选择用于解热,但需进一步验证。
  • 柴胡肌注联合维生素不推荐用于退热,因对比利巴韦林联合维生素未显示效果。

局限性

  • 纳入试验的方法学质量可能影响结果可靠性,证据确定性低至极低。
  • 仅2项试验报告不良事件,安全性数据有限。
  • 样本量有限(共910例),需更大样本、设计良好的临床试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy, clinical effectiveness, and safety of the Chinese herb Bupleuri radix for the treatment of acute uncomplicated respiratory tract infections (ARTIs). Methods: Four English and four Chinese databases were searched from their inception to June 2021. Randomized controlled trials (RCTs) assessing therapeutic effects of Bupleuri radix on ARTI were eligible for inclusion. The risk of bias for each trial was assessed using the Cochrane Risk of Bias Tool 2.0. RevMan 5.4 software was used for data analyses with effects estimated as risk ratios (RR) or mean differences (MD) with 95% confidence intervals (CI). The certainty of the evidence was assessed using the online GRADEpro tool. Results: Seven randomized trials involving 910 patients with acute upper respiratory tract infection (AURTI) were included. The review identified Bupleuri radix agents with four administration routes (oral, acupoint injection, intramuscular injection, nebulized inhalation). Bupleuri radix acupoint injection compared with placebo showed statistically significant effects in reducing fever resolution time (MD: -33.32 h, 95%CI: -35.71, -30.93), and in increasing the proportion of participants with fever resolved within 48 h from treatment onset (RR: 14, 95%CI: 1.96, 99.94). Bupleuri radix acupoint injection combined with usual care is more effective in reducing the temperature at day 1 from treatment onset (MD: -1.00°C, 95%CI: -1.19, -0.81) compared with usual care alone. Bupleuri radix pills showed similar antipyretic effects to acetaminophen. However, Bupleuri radix intramuscular injection plus vitamins failed to demonstrate an effect in reducing fever, when compared with ribavirin plus vitamins. It suggested that oral administration of Bupleuri radix solution for injections, pills, and Bupleuri radix decoction have a similar effect on improving global AURTI symptoms including two key symptoms (nasal discharge and cough), when compared with usual care alone. Only two trials reported whether or not there were any AEs and found no occurrence of adverse events in the herbal group. Conclusion: Low-certainty or very low-certainty evidence demonstrated that Bupleuri radix (solution for injections and pills) has an antipyretic effect on febrile patients with AURTI, but it has no effect on other AURTI symptoms. However, these findings need to be further confirmed by well-designed clinical trials with adequate sample sizes. Systematic review registration: (https://www.crd.york.ac.uk/prospero/#recordDetails), PROSPERO registration number: CRD42021234066.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Yan LJ, Wang ZJ, Fang M, et al. Bupleuri radix for Acute Uncomplicated Respiratory Tract Infection: A Systematic Review of Randomized Controlled Trials. Front Pharmacol. 2022. PMID: 35185539. doi:10.3389/fphar.2021.787084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。